Avalo Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary
12/05/2025 14:32
Avalo Therapeutics Inc AVTX.OQ reported a quarterly adjusted loss of $1.25 per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of $-141.00. The mean expectation of seven analysts for the quarter was for a loss of $1.39 per share. Wall Street expected results to range from $-2.02 to $-1.06 per share. Reported revenue was zero; analysts expected zero. Avalo Therapeutics Inc's reported EPS for the quarter was a loss of $1.25. The company reported a quarterly loss of $13.15 million. Avalo Therapeutics Inc shares had fallen by 49.3% this quarter and lost 45.4% so far this year. FORECAST CHANGES The mean earnings estimate of analysts had fallen by about 14.6% in the last three months. In the last 30 days, there have been no earnings estimate revisions by analysts covering the company. RECOMMENDATIONS The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 7 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is "buy." Wall Street's median 12-month price target for Avalo Therapeutics Inc is $30.00 This summary was machine generated from LSEG data May 12 at 01:31 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
| QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
| Mar. 31 2025 | -1.39 | -1.25 | Beat |
| Dec. 31 2024 | -0.39 | -7.95 | Missed |
| Sep. 30 2024 | -1.19 | -1.25 | Missed |
| Jun. 30 2024 | -6.70 | -14.07 | Missed |